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Background: The receptor activator of NF-κB (RANK), its ligand (RANKL) and osteoprotegerin (OPG) have been
reported to play a role in the pathophysiological bone turnover and in the pathogenesis of breast cancer. Based on
this we investigated the role of single nucleotide polymorphisms (SNPs) within RANK, RANKL and OPG and their
possible association to breast cancer risk.
Methods: Genomic DNA was obtained from Caucasian participants consisting of 307 female breast cancer patients
and 396 gender-matched healthy controls. We studied seven SNPs in the genes of OPG (rs3102735, rs2073618),
RANK (rs1805034, rs35211496) and RANKL (rs9533156, rs2277438, rs1054016) using TaqMan genotyping assays.
Statistical analyses were performed using the χ2-tests for 2 x 2 and 2 x 3 tables.
Results: The allelic frequencies (OR: 1.508 CI: 1.127-2.018, p=0.006) and the genotype distribution (p=0.019) of the
OPG SNP rs3102735 differed significantly between breast cancer patients and healthy controls. The minor allele C
and the corresponding homo- and heterozygous genotypes are more common in breast cancer patients (minor
allele C: 18.4% vs. 13.0%; genotype CC: 3.3% vs. 1.3%; genotype CT: 30.3% vs. 23.5%). No significantly changed risk
was detected in the other investigated SNPs. Additional analysis showed significant differences when comparing
patients with invasive vs. non-invasive tumors (OPG rs2073618) as well as in terms of tumor localization (RANK
rs35211496) and body mass index (RANKL rs9533156 and rs1054016).
Conclusions: This is the first study reporting a significant association of the SNP rs3102735 (OPG) with the
susceptibility to develop breast cancer in the Caucasian population.
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Breast cancer is one of the most common malignancies in
women, leading to distant metastases in patients with
advanced disease, particularly in liver, lung and bone. Bone
metastases are associated with hypercalcemia, pathologic
fracture, spinal cord compression, pain and reduced quality
of life [1]. The discovery of receptor activator of NF-κB
(RANK), its ligand RANKL and osteoprotegerin (OPG)
has contributed significantly to the understanding of the
physiological bone turnover. A functional interaction bet-
ween RANKL, a member of the tumor necrosis factor* Correspondence: jasmin.ney@uks.eu
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reproduction in any medium, provided the or(TNF) ligand superfamily and RANK, its cognate TNF-
receptor is essential for osteoclast differentiation, survival
and activation [2].
RANKL, a type II homotrimeric transmembrane protein,
is expressed by osteoblasts, osteocytes, bone marrow stro-
mal cells, Tcells and various tumor cells, e. g. myeloma and
breast cancer [3-6]. The type-I homotrimeric transmem-
brane protein RANK is not only expressed by osteoclast,
Tcells, dendritic cells, endothelial cells, and mammary
glands but also by cancer cells including prostate and
breast [7-11]. RANKL- or RANK-deficient mice develop
osteopetrosis resulting from a lack of osteoclasts and ab-
sence of bone resorption [12,13]. OPG is a secreted homo-
dimeric glycoprotein from the TNF receptor family,
lacking a transmembrane domain and has homology to the
CD40 protein [14]. OPG neutralizes RANKL, which leads. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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osteoclastogenesis [6,15]. Transgenic mice overexpressing
OPG show increased bone mass (osteopetrosis) as a result
of reduced osteoclasts [14], whereas OPG-deficient mice
are characterized by massive osteoclast activity and osteo-
porosis [16]. With regard to tumor development, OPG is
discussed to be a positive regulator of microvessel forma-
tion and to promote neovascularisation [17] and might
therefore have an influence on tumor progression. More-
over OPG overexpression by breast cancer cells increased
cell proliferation and tumor growth in vivo [18].
A disturbed RANKL/OPG ratio was found in a
spectrum of skeletal diseases (e. g. rheumatoid arthritis,
osteoporosis, bone metastases) characterized by extensive
osteoclast activity. Additionally, the RANK/RANKL path-
way has intrinsic functionality in mammary epithelium de-
velopment. Mice that are deficient for RANK or RANKL
did not develop lactating mammary gland [8]. Recently,
two groups have found that RANKL has not only a funda-
mental role in the normal physiology of the mammary
gland, but may also be crucial for breast cancer develop-
ment [19,20]. These data support earlier results, where
RANKL was shown to play a role in breast cancer cell mi-
gration into bone [21] and underscore the potential use of
RANKL inhibition in the prevention of breast cancer de-
velopment. Based on its pivotal role in the bone remode-
ling process, RANKL has become a therapeutic target. A
monoclonal antibody against RANKL, denosumab, has
been approved for the treatment of postmenopausal
osteoporosis and bone metastasis in breast cancer [22,23].
In summary, the functional properties of the RANK/
RANKL/OPG pathway suggest an important effect of
the genes on the pathogenesis of breast cancer. These
findings led us to investigate the link between seven
single nucleotide polymorphisms (SNPs) in the genes of
RANK, RANKL and OPG, all possibly associated with
functional alterations, and breast cancer risk.
Methods
Study populations
A total of 703 participants consisting of 307 female breast
cancer patients and 396 gender-matched healthy controls
were enrolled in this study (Table 1). All patients and con-
trols were of central European Caucasian ethnicity. Breast
cancer patients were collected from the Department of
Gynecology, Obstetrics and Reproductive Medicine of
Saarland University Medical School, Homburg/Saar,
Germany. Controls were either recruited from the Depart-
ments of Gynecology, Obstetrics and Reproductive Medi-
cine (n=47), Internal Medicine II (n=163) or the Institute
for Transfusion Medicine (n=186) of Saarland University
Medical School, Homburg/Saar, Germany. The local ethics
committee of the Medical Association from the Saarland
(reference number: 162/11) approved the study and allindividuals in the study gave written informed consent.
The study was carried out in compliance with the Helsinki
Declaration.
Case patients were diagnosed as unambiguously having
breast cancer through standard clinical and histological
findings. Specific cancer characteristics such as histo-
logical subtypes, grading, metastasis were not used as a
criterion for the inclusion or exclusion of samples.
SNP selection
The three genes of interest together span more than
120 kb pairs and show only weak to moderate linkage-
disequilibrium patterns according to the HapMap data.
We have preferentially selected SNPs which might be
functionally relevant, either by their location within a po-
tentially regulatory region (3’ untranslated or promoter re-
gion, intron-exon boundary) or by altering the amino acid
sequence (missense mutation). A total of seven SNPs were
analyzed, two within the OPG (rs3102735, rs2073618) and
RANK (rs1805034, rs35211496) gene, respectively, and
three within the RANKL gene (rs9533156, rs2277438,
rs1054016). Table 2 summarizes the chromosomal posi-
tion and function of the selected SNPs.
Genomic DNA extraction and Genotyping
Genomic DNA was isolated from peripheral blood lym-
phocytes using QIAamp DNA Blood Mini Kit according to
the manufacturer’s protocols (Qiagen, Hilden, Germany).
DNA quantity was assessed spectrophotometrically with
the Nanodrop ND 1000 (Peqlab, Erlangen, Germany). All
SNPs were genotyped using commercial TaqMan as-
says (assay IDs: rs3102735: C_1971046_10; rs2073618:
C_1971047_1; rs1805034: C_8685532_20; rs35211496:
C_25473190_10; rs9533156: C_30009803_10; rs2277438:
C_25473654_10; rs1054016: C_7444426_10) with TaqMan
Genotyping Master Mix on a 7500 real-time PCR cycler
(Life Technologies, Darmstadt, Germany) by following the
manufacturer’s instructions.
Statistical analyses
Hardy-Weinberg equilibrium was assessed in each co-
hort by comparing the observed genotype distribution
with the expected one using a χ2-test (Institute of
Human Genetic, Munich, Germany: http://www.ihg.gsf.
de/). The difference in allele and genotype frequencies
between patients and healthy controls (as well as bet-
ween different subgroups) were analyzed using χ2-tests
for 2 x 2 and 2 x 3 tables, respectively, with Fisher’s
exact test. Differences in allele frequencies were quanti-
fied by odds ratios (OR) and 95% confidence intervals
(CI). With regard to significantly elder breast cancer
patients than healthy controls age-adjusted covariate
analysis was performed. All p-values are two-sided and
p-values <0.05 were considered as statistically significant.
Table 1 Characteristics of study population



















Type a, b n=255
Ductal 189 (74%)
Lobular 34 (13%)
Other types 32 (13%)
Unknown 21
Tumor size (T) a, b, c n=229
T1 (< 2 cm) 142 (62%)
T2 (>/= 2 cm – 5 cm) 76 (33%)
T3 (</= 5 cm) 6 (3%)
T4 (infiltration of the chest 5 (2%)
wall/skin)
Unknown 24














Estrogen receptor (ER) d n=275
























Body mass index (BMI) m n=219
BMI < 28 150 (68%)
BMI >/= 28 69 (32%)
Unknown 88
Subgroup a, i n=249
Triple negative 22 (9%)
Non triple negative 227 (91%)
Unknown 30
Subgroup a, j n=262
Risk group 18 (7%)
Non risk group 244 (93%)
Unknown 15
aOnly invasive tumors are included; bBilateral tumors are only included if both
sides had the same result; cExclusion of cases with neoadjuvant
chemotherapy; dImmunoreactive score: 0: negative, 1-12: positive;
eHer2 = human epidermal growth factor receptor 2; immunoreactive score 0-2
(FISH negative): negative, 2 (FISH positive)-3: positive; fKi67 = marker for
proliferation (< 13%: negative, >/= 13%: positive); gCEA = carcinoembryonic
antigen (tumor marker, < 3 ng/ml: negative, >/= 3 ng/ml: positive);
hCA15-3 = tumor marker (< 21 U/ml: negative, >/= 21 U/ml: positive); iTriple
negative = ER, PR and Her2 negative; jRisk group: T >/= 2, G3, ER negative;
FISH = fluorescence in situ hybridization; ksignificant difference (p< 0.001),
age-adjusted statistical analysis performed; mBMI >/= 28 was defined as
overweight in order to age-adjustment [https://www.uni-hohenheim.de/
wwwin140/info/interaktives/bmi.htm].
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Table 2 Selected SNPs for genotyping
Gene SNP number SNP position Allele [major/minor] Function
OPG rs3102735 chr8: 119965070 T/C Transition substitution (5’ near region)
OPG rs2073618 chr8: 119964052 G/C Missense (p.K3N)
RANK rs1805034 chr18: 60027241 T/C Missense (p.V192A)
RANK rs35211496 chr18: 60021761 C/T Missense (p.H141Y)
RANKL rs9533156 chr13: 43147671 T/C Transition substitution (5’ near region)
RANKL rs2277438 chr13: 43155168 A/G Transition substitution (intron1/exon2 boundary)
RANKL rs1054016 chr13: 43182002 G/T Transversion substitution (3’ UTR)
RANK = receptor activator of nuclear factor-κB; RANKL = RANK ligand; SNP = single nucleotide polymorphism; OPG = osteoprotegerin.
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statistical software. Finally, a power analysis was per-
formed using the G power 3.1.3 software. To the best of
our knowledge no adjustment for multiple testing was
made because analyses were considered exploratory and
needing confirmation by an independent set of data. Pre-
vious studies have demonstrated that the analyzed SNPs
only show a weak to moderate linkage-disequilibrium
patterns according to the HapMap data.
Results
Subject characteristics
The mean age was 56 years (range 22-91) for the breast
cancer patients and 45 (range 18-88) for the healthy con-
trols showing significant difference. Clinical data (e. g.
menopausal status, body mass index (BMI)) and specific
cancer characteristics such as localization, histological
subtypes, tumor size, metastasis, grading, proliferation
index as well as hormone receptor and Her2 expression
are listed in Table 1. The tumor markers carcinoembryo-
nic antigen (CEA) and CA15-3 were measured routinely
in the blood of preoperative patients. Invasive ductal car-
cinomas (74%) with a size smaller 2 cm (T1, 62%) and
without metastases (nodal negative: 70%, no distant me-
tastases: 95%) at first diagnosis were most frequently.
Additionally, most tumors expressed estrogen (81%) and
progesterone receptors (70%), as expected, while Her2
was negative in most cases (80%) (Table 1).
Allele and genotype frequencies and risk of breast cancer
The genotype distributions for all seven SNPs were in the
Hardy-Weinberg equilibrium. Table 3 summarizes the
results of all SNP analyses in the genes encoding for OPG
(rs3102735, rs2073618), RANK (rs1805034, rs35211496)
and RANKL (rs9533156, rs2277438, rs1054016). Allelic
and genotype frequencies in breast cancer patients were
compared to healthy controls.
The allelic frequencies (OR: 1.508 CI: 1.127-2.018,
p=0.006) as well as the genotype distribution (p=0.019) of
the OPG SNP rs3102735 differed significantly between
breast cancer patients and healthy controls. The minor al-
lele C was more frequent in breast cancer patients (18.4%)compared to the control group (13.0%). In addition, the
homozygous genotype CC of the minor allele as well as
the heterozygous genotype CT were more frequent in the
breast cancer group (3.3% and 30.3%) compared to the
controls (1.3% and 23.5%) (Table 3). The power analysis
revealed a power of 0.79 for the allele frequency and
0.72 for the genotype distribution to detect dependencies
(α = 0.05) (Additional file 1: Figure S1). Further statistical
analysis revealed that the heterozygous genotype CT as
well as the homozygous genotype CC together with the
heterozygous genotype CT versus the homozygous geno-
type TT of the major allele significantly differed between
breast cancer patients and controls (CT vs. TT: OR: 1.462,
CI 1.042-2.052, p=0.030; [CC + CT] vs. TT: OR: 1.536, CI
1.104-2.135, p=0.011). Due to significantly differences in
the median age between controls and breast cancer
patients (Table 1) we confirmed these data with a logistic
regression using age as a covariate (p=0.005).
No significant differences in the allele frequencies and
genotype distributions were found, when the breast cancer
patients were compared with the controls for the other
SNPs analyzed in this study.
Association between SNPs within different breast cancer
subgroups
Next we examined the association between the distribution
of genotypes and allelic frequencies of all analyzed SNPs
and clinicopathological data including tumor localization,
histological subtypes, tumor size, metastasis, grading, prolif-
eration index, hormone receptor expression, Her2 expres-
sion, tumor marker level, menopausal status as well as
body mass index at the time of diagnosis (Table 1).
Regarding the two OPG SNPs the most interesting re-
sult was the significant difference in genotype distribution
and allelic frequency of OPG rs2073618 between invasive
versus non invasive tumors. The homozygous major geno-
type GG (31.3% vs. 21.4%, p=0.006) as well as the major
allele G (57.5% vs. 39.3%, OR 2.088 CI 1.189-3.663,
p=0.011) were more frequent in patients with invasive
tumors in contrast to non-invasive ones (Table 4).
Another important difference was found with respect to
the genotype distribution as well as the allelic frequency
Table 3 Association of allele and genotype frequencies of OPG, RANK and RANKL in patients with breast cancer and
healthy controls
SNP Alleles / Genotypes Breast cancer Healthy controls OR (95% CI) p-value*
OPG rs3102735 n=614 (%) n=784 (%)
Alleles C 113 (18.4%) 102 (13.0%) 1.508 0.006
T 501 (81.6%) 682 (87.0%) (1.127-2.018)
n=307 (%) n=392 (%)
Genotypes CC 10 (3.3%) 5 (1.3%) 0.019
CT 93 (30.3%) 92 (23.5%)
TT 204 (66.4%) 295 (75.3%)
OPG rs2073618 n=614 (%) n=786 (%)
Alleles C 269 (43.8%) 357 (45.4%) 0.937 0.552
G 345 (56.2%) 429 (54.6%) (0.758-1.159)
n=307 (%) n=393 (%)
Genotypes CC 57 (18.6%) 77 (19.6%) 0.810
CG 155 (50.5%) 203 (51.7%)
GG 95 (30.9%) 113 (29.7%)
RANK rs1805034 n=614 (%) n=790 (%)
Alleles C 291 (47.4%) 362 (45.8%) 1.065 0.590
T 323 (52.6%) 428 (54.2%) (0.862-1.316)
n=307 (%) n=395 (%)
Genotypes CC 73 (23.8%) 78 (19.7%) 0.334
CT 145 (47.2%) 206 (52.2%)
TT 89 (29.0%) 111 (28.1%)
RANK rs35211496 n=614 (%) n=792 (%)
Alleles T 122 (19.9%) 141 (17.8%) 1.145 0.335
C 492 (80.1%) 651 (82.2%) (0.875-1.499)
n=307 (%) n=396 (%)
Genotypes TT 12 (3.9%) 9 (2.3%) 0.423
TC 98 (31.9%) 123 (31.1%)
CC 197 (64.2%) 264 (66.7%)
RANKL rs9533156 n=614 (%) n=788 (%)
Alleles C 280 (45.6%) 369 (46.8%) 0.952 0.666
T 334 (54.4%) 419 (53.2%) (0.770-1.176)
n=307 (%) n=394 (%)
Genotypes CC 68 (22.1%) 82 (20.8%) 0.387
CT 144 (46.9%) 205 (52.0%)
TT 95 (30.9%) 107 (27.2%)
RANKL rs2277438 n=614 (%) n=788 (%)
Alleles G 109 (17.8%) 132 (16.8%) 1.073 0.669
A 505 (82.2%) 656 (83.2%) (0.812-1.418)
n=307 (%) n=394 (%)
Genotypes GG 8 (2.6%) 9 (2.3%) 0.866
GA 93 (30.3%) 114 (28.9%)
AA 206 (67.1%) 271 (68.8%)
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Table 3 Association of allele and genotype frequencies of OPG, RANK and RANKL in patients with breast cancer and
healthy controls (Continued)
RANKL rs1054016 n=614 (%) n=786 (%)
Alleles T 258 (42.0%) 345 (43.9%) 0.927 0.514
G 356 (58.0%) 441 (56.1%) (0.749-1.147)
n=307 (%) n=393 (%)
Genotypes TT 57 (18.6%) 73 (18.6%) 0.543
TG 144 (46.9%) 199 (50.6%)
GG 106 (34.5%) 121 (30.8%)
CI = confidence intervals; RANK = receptor activator of nuclear factor-κB; RANKL = RANK ligand; OPG = osteoprotegerin; OR = odds ratio; *χ2-tests for 2x2 tables
(alleles) and for 2x3 tables (genotypes), respectively.
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breast) for the RANK SNP rs35211496. The homozygous
minor allele T (25.2% vs. 15.3% OR 1.863 CI 1.236-2.808,
p=0.003) and the minor allele genotype TT (7.3% vs. 1.7%,
p=0.009) were more frequent in patients with tumor in-
volvement of the right breast in contrast to the left side
(Table 4).
The allelic frequencies (rs9533156: OR 1.543 CI 1.029-
2.315, p=0.038; rs1054016: OR 1.630 CI 1.083-2.453,
p=0.021) as well as the genotype distribution (rs9533156:
p=0.032; rs1054016: p=0.018) of the RANKL SNPs
rs9533156 and rs1054016 differed significantly between
patients with a higher BMI (>/= 28) compared to patients
with a lower BMI (< 28) at the first diagnosis. The minor
allele C for SNP rs9533156 and T concerning the SNP
rs1054016 were more frequent in patients with a BMI
>/= 28 (rs9533156: 50.7%; rs1054016: 47.8%) compared toTable 4 Association of allele and genotype frequencies within
SNP Alleles
OPG rs2073618 G C
Invasive tumors 316 (57.5%) 234 (42.5%)
Non-invasive tumors 22 (39.3%) 34 (60.7%)
OR (95%CI) p-value* 2.088 (1.189-3.663) p=0.011
RANK rs35211496 T C
right breasta 62 (25.2%) 184 (74.8%)
left breasta 53 (15.3%) 293 (84.7%)
OR (95%CI) p-value* 1.863 (1.236-2.808) p=0.003
RANKL rs9533156 C T
BMI >/=28 70 (50.7%) 68 (49.3%)
BMI <28 120 (40%) 180 (60%)
OR (95%CI) p-value* 1.543 (1.029-2.315) p=0.038
RANKL rs1054016 T G
BMI >/=28 66 (47.8%) 72 (52.2%)
BMI <28 108 (36.0%) 192 (64.0%)
OR (95%CI) p-value* 1.630 (1.083-2.453) p=0.021
BMI = body mass index; CI = confidence intervals; RANK = receptor activator of nuc
*χ2-tests for 2x2 (alleles) and 2x3 (genotypes) tables, respectively; aExclusion of case
Data not shown concerning the remaining SNPs stratified into further subgroups acpatients with a lower BMI (rs9533156: 40%, rs1054016:
36%; Table 4).
No significant differences in the allele frequencies and
genotype distributions were found in the different subgroup
analyses (including distant metastases) for the remaining
analyzed SNPs (data not shown).
Discussion
To the best of our knowledge, this is the first study
showing a significant association between the SNP
rs3102735 of the OPG gene and the susceptibility of
breast cancer in Caucasian populations. For the SNP
rs3102735 containing the minor allele C as well as for
the homo- and heterozygous genotype with the minor
allele C, we observed a 1.5-fold increased risk of breast
cancer. All other SNPs were not associated with an
increased risk for breast cancer. These results suggest aselected breast cancer subgroups
Genotypes
GG CG CC
86 (31.3%) 144 (52.4%) 45 (16.4%)
6 (21.4%) 10 (35.7%) 12 (42.9%)
p=0.006
TT TC CC
9 (7.3%) 44 (35.8%) 70 (56.9)
3 (1.7%) 47 (27.2%) 123 (71.1%)
p=0.009
CC CT TT
22 (31.9%) 26 (37.7%) 21 (30.4%)
24 (16.0%) 72 (48.0%) 54 (36.0%)
p=0.032
TT TG GG
20 (29.0%) 26 (37.7%) 23 (33.3%)
19 (12.7%) 70 (46.7%) 61 (40.7%)
p=0.018
lear factor-κB; RANKL = RANK ligand; OPG = osteoprotegerin; OR = odds ratio;
s with bilateral tumor involvement.
cording to Table 1.
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breast cancer development.
Previous studies showed that genetic variants in the OPG
locus have been associated with differences in bone mineral
density (BMD; [24-33], osteoporotic fractures [28,34], bone
turnover [31], bisphosphonate-induced osteonecrosis of
the jaw [35], calcaneal quantitative ultrasound (velocity of
sound) [36], ankylosing spondylitis development [37] and
diabetic charcot neuroarthropathy [38].
In detail, concerning the rs3102735 SNP the G allele was
more common among fracture patients [28,34] and
patients with lower BMD at the distal radius [30]. Further-
more, there is an association within a subgroup of postme-
nopausal patients carrying the minor allele and a lower
calcaneal velocity of sound [36]. In an earlier study the
variation (rs3102735) within the OPG gene showed a trend
with higher frequency of the minor allele (p=0.076) and
responding genotypes (p=0.097) in patients with psoriasis
compared to controls without reaching significance [39].
Recently, several genome wide association studies or
studies of specific candidate SNPs revealed additional
loci to be associated with breast cancer including the
same chromosomal region 8q24 as for the OPG gene
[40-49]. The majority of the association on chromosome
8q24 lies at approximately 128 Mb and is related to
several tumor entities (prostate [50], colon [51]) in
addition to breast cancer. Each locus within the 128 Mb
bears epigenetic enhancer elements and forms chroma-
tin loops with the myc proto-oncogene located several
hundred kilobases telomeric [52]. A recent meta-analysis
revealed an additional locus around 120 Mb on chromo-
some 8 associated with cancer development [53]. This
region is close to the locus of OPG rs3102735 SNP
(chromosome 8q24 119.965.070), which is associated
with breast cancer in our study.
In this context we found a second genetic variation
within the rs2073618 SNP of the OPG gene when strati-
fying our breast cancer patients into the subgroups of
invasive or non-invasive tumors. However, the impact of
the SNPs rs3102735 (5’ near promoter region) and
rs2073618, located in the first exon, which encodes the
signal peptide of OPG, are still unclear. Zhao et al. dis-
cussed that the change of the third amino acid from ly-
sine (basic amino acid) to asparagine (uncharged polar
amino acid) may have an influence of the OPG secretion
from the cells. In their study they found that patients
carrying the CC genotype had lower serum level of OPG
[33]. In another study, a mutation in a basic amino acid
(arginin) in the signal peptide of angiotensinogen dras-
tically affected the secretory kinetics [54]. However, the
exact mechanism that the SNP rs2073618 possibly
affects the secretory characteristics of OPG needs to be
elucidated by further functional studies. Genetic varia-
tion within the promoter region of OPG (rs3102735)could have an effect on the OPG gene expression and
thus an influence on tumor development.
Further subgroup analyses according to clinical para-
meters showed an association with BMI (<28 or >/=28).
In general, increased BMI is associated with the risk of
some cancers and might differ between sexes and diffe-
rent ethnic populations such as breast cancer [55]. Com-
bined studies revealed that the increase in breast cancer
risk with increasing BMI among postmenopausal women
is mostly depending on associated increase in bioavail-
able estradiol [56]. Here we show that the minor allele
as well as the genotype of the minor allele of the RANKL
SNPs rs9533156 and rs1054016 were strongly associated
with a higher BMI (>/= 28) in the breast cancer group.
Whether obese patients carrying the minor allele from
one of the two RANKL SNPs have an additionally a higher
risk of developing breast cancer remains open in this
study due to the lack of BMI data from the control group.
Moreover, we confirmed an asymmetry of breast carci-
noma to the left side (57% vs. 40%, Table 1) in accordance
with several other studies, which revealed asymmetries in
paired organs including breast [57,58], the lungs [59], kid-
ney [60] and testes [61]. Especially for the unsymmetric
incidence of breast cancer in favour of the left side, several
possible explanations are discussed, including the sleeping
habit [62], handedness [63], the preference for breast fee-
ding [64] or breast size [63]. We found that a genetic va-
riation within the rs35211496 RANK SNP could have an
influence on the tumor localization. Whether this poly-
morphism has a direct effect on the unsymmetric inci-
dence or indirectly via the breast size can not be answered
from this study.
The subgroup analyses stratified into metastatic disease
at initial diagnosis showed no significant differences in
genotype or allelic distribution. Only 10 of 292 patients
were primarily diagnosed with bone metastases. Further
studies focusing on skeletal metastases with respect to
genetic background are required.
Other genetic variants at the RANK locus and/or func-
tionally related genes, including RANKL have been asso-
ciated with differences in bone mineral density [31],
rheumatoid arthritis [65,66], aortic calcification [67], age
at menarche [68] or Paget′s disease of bone [69]. There is
one recent study which showed a genetic variant near the
5′-end of RANK (rs7226991) associated with a breast can-
cer risk [70].
Conclusion
Our case-control study points to an association of the OPG
SNP rs3102735 with an increased risk of developing breast
cancer. These results could extend the constellation of pos-
sible breast cancer risk and might affect early diagnosis.
Future studies are needed, including confirmation of
our observation in an independent validation set, to
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and breast cancer risk in other ethnic groups. Whether
this SNP leads to a functional alteration of OPG expres-
sion and consequently to an altered RANKL level remains
to be shown.
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